Substance / Medication

Colloidal bismuth subcitrate

Overview

Active Ingredient
bismuth subcitrate
RxNorm CUI
47181

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Acute renal failure after overdose of colloidal bismuth subcitrate.
Cengiz Nurcan, Uslu Yasemin, Gök Faysal et al. · Pediatr Nephrol · 2005
PMID: 15947979Case Report
Fanconi's syndrome, acute renal failure, and tonsil ulcerations after colloidal bismuth subcitrate intoxication.
Hruz Petr, Mayr Michael, Löw Roland et al. · Am J Kidney Dis · 2002
PMID: 11877598Case Report
Reversible nephrotoxicity after overdose of colloidal bismuth subcitrate.
Işlek I, Uysal S, Gök F et al. · Pediatr Nephrol · 2001
PMID: 11420918Case Report
Endocytic pathways and metabolic fate of colloidal bismuth subcitrate in human renal cells.
Yang Yang, Tan Mengfei, Cui Jinbin et al. · Chem Biol Interact · 2024
PMID: 39332791Other
Evaluation and comparison of therapeutic effects of probiotics and colloidal bismuth subcitrate on abdominal bloating.
Soheilipour Maryam, Tabesh Elham, Najmi Soheila et al. · Caspian J Intern Med · 2023
PMID: 37520877OtherFull text (PMC)
In vitro evaluation of the antibacterial effect of colloidal bismuth subcitrate on Porphyromonas gingivalis and its biofilm.
Gong Min, Zhang Rui, Qi Jianyan et al. · Arch Oral Biol · 2022
PMID: 34742000Other
Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate.
Tao Xuan, Zhang Lu, Du Liubing et al. · Chem Sci · 2021
PMID: 34760193OtherFull text (PMC)
Eradication ofPersisters Through Colloidal Bismuth Subcitrate Synergistically Combined With Metronidazole.
Wang Chuan, Li Xuan, Cheng Tianfan et al. · Front Microbiol · 2021
PMID: 34745052OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Colloidal bismuth subcitrate (substance)
SNOMED CT
396007005
UMLS CUI
C0106556
RxNorm CUI
47181

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.